Drug intelligence / Profile preview

enterovirus 71 vaccine + aluminum hydroxide

Development stage
Unknown
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Enterovirus 71 vaccine with aluminum hydroxide refers to a class of inactivated viral vaccines developed to prevent hand, foot, and mouth disease (HFMD) and herpangina caused by Enterovirus 71 (EV71). These vaccines are typically produced using Vero cells or human diploid cells, where the virus is inactivated (e.g., using formaldehyde or binary ethylenimine) and then adsorbed onto an aluminum hydroxide adjuvant to enhance the immune response. Several versions have been developed by different organizations, including **Sinovac Biotech**, the **Institute of Medical Biology at the Chinese Academy of Medical Sciences (IMBCAMS)**, and **Takeda Pharmaceuticals**. Clinical trials, particularly Phase 3 studies in China, have demonstrated that these vaccines are highly efficacious, often exceeding 90% protection against EV71-associated HFMD in infants and young children. The vaccines work by inducing high titers of neutralizing antibodies that prevent viral entry and replication.

Brand names
InliveGinvax
Other names
Inactivated enterovirus 71 vaccineEV71 vaccineEV-71 vaccineEV 71 vaccineEnterovirus 71 vaccine (inactivated)
02

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on enterovirus 71 vaccine + aluminum hydroxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on enterovirus 71 vaccine + aluminum hydroxide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call